In August, the company announced people who had obesity or were overweight without diabetes lost 12% of their body weight on average with the orforglipron pill after 72 weeks in a late-stage trial
Retatrutide (triple GLP-1/GIP/glucagon receptor agonist): At 24 weeks, the 12 mg dose achieved 17.5% body weight reduction
Recent studies show the FDA is now exploring GLP-1s as a potential medication-assisted treatment for addiction
If one supplier is 60-70% cheaper than the market average, proceed with extreme caution and demand independent third-party testing before committing to a large order
As such, people may consider other approaches such as weight loss programs and surgery options
I thought, Anna, youve got to get yourself together. Three months after the roller coaster incident, Wysock got a prescription for Mounjaro, an injectable diabetes drug that can be used for weight loss